Results 31 to 40 of about 5,550 (180)

Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms.

PLoS ONE, 2021
Myeloproliferative neoplasms (MPNs) cause the over-production of blood cells such as erythrocytes (polycythemia vera) or platelets (essential thrombocytosis).
Ron Baik, Stacia K Wyman, Shaheen Kabir, Jacob E Corn   +3 more
doaj   +1 more source

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [PDF]

Leukemia, 2005
n ...
ANTONIOLI, ELISABETTA, GUGLIELMELLI, PAOLA, PANCRAZZI, ALESSANDRO, BOGANI, COSTANZA, Verrucci M, PONZIANI, VANESSA, Longo G, BOSI, ALBERTO, VANNUCCHI, ALESSANDRO MARIA   +8 more
openaire   +4 more sources

Molecular screening for an underlying myeloproliferative neoplasm in rheumatology patients

The Turkish Journal of Gastroenterology, 2022
The hematological manifestations of rheumatic diseases are varied with therapeutic agents also capable of inducing hematological abnormalities such as cytopenias.[1] Some of these hematological features can mimic those of the myeloproliferative ...
Stephen Langabeer
doaj  

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with budd-chiari syndrome and/or portal vein thrombosis

The Turkish Journal of Gastroenterology, 2015
Background/Aims: The diagnosis of an underlying myeloproliferative neoplasm (MPN) is often problematic in patients with Budd Chiari syndrome (BCS) or portal vein thrombosis (PVT).
Süleyman Karaköse, Nevin Oruç, Melia Zengin, Ulus Salih Akarca, Galip Ersöz   +4 more
doaj   +1 more source

Atypical Myocardial Infarction with Apical Thrombus and Systemic Embolism: A Rare Presentation of Likely JAK2 V617F-Positive Myeloproliferative Neoplasm

Case Reports in Oncological Medicine, 2020
A few types of myeloproliferative neoplasms may be significant for Janus-associated kinase 2 mutation, JAK2 V617F, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Muhammed Atere, Rana Al-Zakhari, Jennifer Collins, Francesco Rotatori, Lloyd Muzangwa   +4 more
doaj   +1 more source

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

Haematologica, 2007
We compared the laboratory and clinical findings of 179 patients with essential thrombocythemia (ET) and 77 with polycythemia vera (PV) classified according to the presence of the JAK2 V617F mutation.
Guido Finazzi, Alessandro Rambaldi, Vittoria Guerini, Alessandra Carobbo, Tiziano Barbui   +4 more
doaj   +1 more source

PCR-HRM for Detecting JAK2V617F Gene Mutation: Is It a Sensitive Assay?

Basic & Clinical Cancer Research, 2020
Background: A substitution of G to T at nucleotide 1849 in exon 14 of the Janus kinase2 (JAK2) gene is recognized to MPNs disorders. Based on WHO guidelines detection of the mutation is very important to confirm the disease in the suspected patients ...
Mitra Rezaei, Mihan PourAbdollah Toutkaboni, Babak Salimi, Sharareh Seifi, Fatemeh Maryam Sheikholeslami   +4 more
doaj   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation

Haematologica, 2013
Myeloproliferative disorders are associated with increased risk of thrombosis and vascular complications. The pathogenesis of these complications is not completely known.
Margarita Hurtado-Nedelec, Marie-José Csillag-Grange, Tarek Boussetta, Sahra Amel Belambri, Michèle Fay, Bruno Cassinat, Marie-Anne Gougerot-Pocidalo, Pham My-Chan Dang, Jamel El-Benna   +8 more
doaj   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source